You are here:
Two key factors set the Vaccine Alliance apart from other actors in the field of international health aid:
In this section, we explain Gavi’s unique business model and the six ways it delivers "added value".
Donor and developing countries need to see proof of the value of new vaccines before investing.
Immunisation is a commitment for life that requires guaranteed, long-term funding.
Developing countries decide for themselves how best to use Gavi support for immunisation.
It's not enough to buy new vaccines. They have to safely reach every child.
Gavi’s market shaping efforts aim to make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.
National immunisation programes must survive long after Gavi support stops.
Nearly 19 million infants remain unimmunised in the world each year.
22 August 2015
Vaccinations Bring Hope, Bracelets Deliver Reminders
The New York Times
24 July 2015
Malaria vaccine: How good is good enough?
23 July 2015
Sudan's other crisis
03 July 2015
Investment in child health in world's poorest countries saves 34m lives
01 May 2015
Immunisation gives children chance to live life to full potential
22 April 2015
The imperative of closing the immunization gap
03 March 2015
Ebola vaccine research in Africa
02 October 2013
Laos becomes first South East Asian nation to introduce pneumococcal vaccine
04 May 2013
Sojo Stories: Immunizing 250 Million Children By 2015
27 March 2013
Seth Berkley on Immunization in Pakistan
Heartfile eForum Blog
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2015
modal window here